Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392545 | 0.77 | HTR7 (0.46) | POLBALDH1A1TSHRL3MBTL1RECQL | |
| SCHEMBL3388921 | 0.76 | HTR7 (0.35) | POLBALDH1A1TSHRL3MBTL1RECQL | |
| SCHEMBL5604212 | 0.74 | HTR7 (0.34) | GAAMCOLN3HTR7 | |
| SCHEMBL3392538 | 0.68 | HTR7 (0.38) | POLBGAAMCOLN3HTR7 | |
| SCHEMBL6095183 | 0.62 | HTR7 (0.46) | TSHRGAAMCOLN3HTR7NPC1 | |
| SCHEMBL7928278 | 0.61 | HTR7 (0.36) | GAAMCOLN3HTR7 | |
| SCHEMBL31147497 | 0.61 | MAOA (0.41) | POLBALDH1A1TSHRL3MBTL1GAA | |
| SCHEMBL3388221 | 0.60 | POLB (0.44) | POLBALDH1A1TSHRL3MBTL1RECQL | |
| 1,4-Butanediol SCHEMBL28575010 | 0.60 | TSHR (0.73) | POLBALDH1A1TSHRESR2TDP1 | |
| SCHEMBL4613715 | 0.59 | TSHR (0.42) | TSHRL3MBTL1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101180041-B | Therapeutic agent for sensory disorder | MEIJI DAIRIES CORP | 2011-04-13 | — | — | CN | disclosed |
| EP-1839653-B9 | THERAPEUTIC AGENT FOR SENSORY DISORDERS | MEIJI DAIRIES CORP (JP) | 2010-12-22 | — | — | EP | disclosed |
| EP-2196200-A1 | Cyclohexenone derivative for treating or preventing hypesthesia or hyperesthesia caused by diabetes | Meiji Dairies Corporation (JP) | 2010-06-16 | — | — | EP | disclosed |
| EP-1839653-B1 | THERAPEUTIC AGENT FOR SENSORY DISORDERS | MEIJI DAIRIES CORP (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090069442-A1 | Therapeutic Agent for Sensory Abnormality | MEIJI CO., LTD (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20080312336-A1 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder | UNIVERSITE DE STRASBOURG (FR) | 2008-12-18 | — | — | US | disclosed |
| CN-101180041-A | Therapeutic agent for sensory disorder | MEIJI DAIRIES CORP (JP) | 2008-05-14 | — | — | CN | disclosed |
| EP-1839653-A1 | THERAPEUTIC AGENT FOR SENSORY ABNORMALITY | Meiji Dairies Corporation (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-7166642-B1 | Use of cyclohexenone long-chain alcohol for treating neurodegenerative diseases | MEIJI DAIRIES CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| EP-1150667-B1 | CYCLOHEXENONE LONG-CHAIN ALCOHOL FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | MEIJI DAIRIES CORP (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-1003706-B1 | CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME | MEIJI MILK PROD CO LTD (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-6228893-B1 | TREATING DEMENTIA | MEIJI MILK PRODUCTS CO., LTD. (JP) | 2001-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312336-A1 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder | CPT1B, CHRM1, ADRA1D | POLB 1865/4885ALDH1A1 416/4885TSHR 3173/4885 |
| US-20090069442-A1 | Therapeutic Agent for Sensory Abnormality | PMP22, NGF, HRH1 | POLB 3695/4885ALDH1A1 200/4885TSHR 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.